- Home
- TNXP vs CFBK Comparison
TNXP vs CFBK Comparison
Compare TNXP & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TNXP | CFBK |
|---|---|---|
| Founded | 2007 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.9M | 167.9M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | TNXP | CFBK |
|---|---|---|
| Price | $15.63 | $25.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $70.00 | $29.00 |
| AVG Volume (30 Days) | ★ 507.7K | 74.4K |
| Earning Date | 11-10-2025 | 02-11-2026 |
| Dividend Yield | N/A | ★ 1.25% |
| EPS Growth | N/A | ★ 21.79 |
| EPS | N/A | ★ 2.49 |
| Revenue | $10,299,000.00 | ★ $50,724,000.00 |
| Revenue This Year | $2.96 | $39.98 |
| Revenue Next Year | $750.19 | $10.47 |
| P/E Ratio | ★ N/A | $10.26 |
| Revenue Growth | N/A | ★ 14.25 |
| 52 Week Low | $6.76 | $19.23 |
| 52 Week High | $69.97 | $27.46 |
Technical Indicators
Market Signals| Indicator | TNXP | CFBK |
|---|---|---|
| Relative Strength Index (RSI) | 36.58 | 58.53 |
| Support Level | $15.47 | $24.32 |
| Resistance Level | $16.95 | $26.46 |
| Average True Range (ATR) | 0.96 | 0.79 |
| MACD | -0.21 | -0.08 |
| Stochastic Oscillator | 5.90 | 37.78 |
Price Performance
Historical ComparisonAbout TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.